Market: NASD |
Currency: USD
Address: 3960 Howard Hughes Parkway
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Show more
📈 PharmaCyte Biotech, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
>500%
-
Net Income Growth Range (1Y):
>500%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2021 |
- |
$0.000645 |
- |
2021-07-12 |
- |
Stock split |
|
Total Amount for 2021: $0.000645 |
📅 Earnings & EPS History for PharmaCyte Biotech, Inc.
| Date | Reported EPS |
|---|
| 2022-09-14 | -0.07 |
| 2022-07-28 | -0.06 |
| 2022-03-15 | -0.04 |
| 2021-12-14 | -0.06 |
| 2015-08-25 | - |
| 2015-07-29 | -15 |
📰 Related News & Research
No related articles found for "pharmacyte biotech".
